These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524 [TBL] [Abstract][Full Text] [Related]
5. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. Trakulsomboon S; Danchaivijitr S; Rongrungruang Y; Dhiraputra C; Susaemgrat W; Ito T; Hiramatsu K J Clin Microbiol; 2001 Feb; 39(2):591-5. PubMed ID: 11158112 [TBL] [Abstract][Full Text] [Related]
6. Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains. Bernard L; Vaudaux P; Rohner P; Huggler E; Armanet M; Pittet D; Lew DP; Schrenzel J J Microbiol Methods; 2004 May; 57(2):231-9. PubMed ID: 15063063 [TBL] [Abstract][Full Text] [Related]
7. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Hiramatsu K Am J Med; 1998 May; 104(5A):7S-10S. PubMed ID: 9684652 [TBL] [Abstract][Full Text] [Related]
8. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. Ike Y; Arakawa Y; Ma X; Tatewaki K; Nagasawa M; Tomita H; Tanimoto K; Fujimoto S J Clin Microbiol; 2001 Dec; 39(12):4445-51. PubMed ID: 11724859 [TBL] [Abstract][Full Text] [Related]
9. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. Hanaki H; Kuwahara-Arai K; Boyle-Vavra S; Daum RS; Labischinski H; Hiramatsu K J Antimicrob Chemother; 1998 Aug; 42(2):199-209. PubMed ID: 9738837 [TBL] [Abstract][Full Text] [Related]
10. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Dilworth TJ; Leonard SN; Vilay AM; Mercier RC Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667 [TBL] [Abstract][Full Text] [Related]
11. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Hawser SP; Bouchillon SK; Hoban DJ; Dowzicky M; Babinchak T Int J Antimicrob Agents; 2011 Mar; 37(3):219-24. PubMed ID: 21239146 [TBL] [Abstract][Full Text] [Related]
12. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Oliveira GA; Dell'Aquila AM; Masiero RL; Levy CE; Gomes MS; Cui L; Hiramatsu K; Mamizuka EM Infect Control Hosp Epidemiol; 2001 Jul; 22(7):443-8. PubMed ID: 11583214 [TBL] [Abstract][Full Text] [Related]
13. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. Steinkraus G; White R; Friedrich L J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693 [TBL] [Abstract][Full Text] [Related]
14. Effect of vancomycin on the cytoplasmic membrane fatty acid profile of vancomycin-resistant and -susceptible isolates of Staphylococcus aureus. Mirani ZA; Jamil N J Infect Chemother; 2013 Feb; 19(1):24-33. PubMed ID: 22821354 [TBL] [Abstract][Full Text] [Related]
15. [Reliability of disc-diffusion susceptibility testing for arbekacin, vancomycin and teicoplanin against methicillin-resistant Staphylococcus aureus]. Kouda M; Homma S; Udagawa I; Tamura K; Fukuhara J; Takeuchi M Jpn J Antibiot; 1999 Dec; 52(12):681-9. PubMed ID: 10695023 [TBL] [Abstract][Full Text] [Related]
16. Vancomycin MICs of the resistant mutants of S. aureus ATCC43300 vary based on the susceptibility test methods used. Zhu YL; Mei Q; Hu LF; Cheng J; Ye Y; Li JB J Antibiot (Tokyo); 2012 Jun; 65(6):307-10. PubMed ID: 22491134 [TBL] [Abstract][Full Text] [Related]
17. Emergence of vancomycin resistance during therapy against methicillin-resistant Staphylococcus aureus in a burn patient--importance of low-level resistance to vancomycin. Haraga I; Nomura S; Fukamachi S; Ohjimi H; Hanaki H; Hiramatsu K; Nagayama A Int J Infect Dis; 2002 Dec; 6(4):302-8. PubMed ID: 12718825 [TBL] [Abstract][Full Text] [Related]
19. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. Wang G; Hindler JF; Ward KW; Bruckner DA J Clin Microbiol; 2006 Nov; 44(11):3883-6. PubMed ID: 16957043 [TBL] [Abstract][Full Text] [Related]
20. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. Alós JI; García-Cañas A; García-Hierro P; Rodríguez-Salvanés F J Antimicrob Chemother; 2008 Oct; 62(4):773-5. PubMed ID: 18552338 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]